Histopathological growth pattern, proteolysis and angiogenesis in chemonaive patients resected for multiple colorectal liver metastases

Journal of Oncology

Volumn , Issue , 2012, Pages

  Eefsen, Rikke Lovendahl ^a,b,c   Van Den Eynden, Gert G ^d   Hoyer Hansen, Gunilla ^b,c   Brodt, Pnina ^e   Laerum, Ole Didrik ^b,c,f   Vermeulen, Peter B ^d   Christensen, Ib Jarle ^b,c   Wettergren, André ^a   Federspiel, Birgitte ^a   Willemoe, Gro L ^a   Vainer, Ben ^a   Osterlind, Kell ^a   Illemann, Martin ^b,c,e  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d GZA Hospitals St Augustinus   (Belgium)

^e MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^f HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

UROKINASE RECEPTOR;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PATIENT; CANCER SURGERY; CLINICAL ARTICLE; COLORECTAL CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; MALE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; UPREGULATION;

EID: 84866252452     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/907971     Document Type: Article

References (40)

1. Siegel R., Naishadham D., Jemal A., Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 2012 62 1 10 29
2. Brachet D., Lermite E., Rouquette A., Lorimier G., Hamy A., Arnaud J. P., Prognostic factors of survival in repeat liver resection for recurrent colorectal metastases: review of sixty-two cases treated at a single institution. Diseases of the Colon and Rectum 2009 52 3 475 483 2-s2.0-64549109797 10.1007/DCR.0b013e31819d12bc
3. Khatri V. P., Chee K. G., Petrelli N. J., Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surgical Oncology 2007 16 1 71 83 2-s2.0-34249944298 10.1016/j.suronc.2007.05.001 (Pubitemid 46880341)
4. McMillan D. C., McArdle C. S., Epidemiology of colorectal liver metastases. Surgical Oncology 2007 16 1 3 5 2-s2.0-34250021354 10.1016/j.suronc.2007.04.008
5. Hurwitz H., Fehrenbacher L., Novotny W., Cartwright T., Hainsworth J., Heim W., Berlin J., Baron A., Griffing S., Holmgren E., Ferrara N., Fyfe G., Rogers B., Ross R., Kabbinavar F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. The New England Journal of Medicine 2004 350 23 2335 2342 2-s2.0-2542561964 10.1056/NEJMoa032691 (Pubitemid 38702844)
6. Tabernero J., Van Cutsem E., Díaz-Rubio E., Cervantes A., Humblet Y., André T., Van Laethem J. L., Soulié P., Casado E., Verslype C., Valera J. S., Tortora G., Ciardiello F., Kisker O., De Gramont A., Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. Journal of Clinical Oncology 2007 25 33 5225 5232 2-s2.0-36749067866 10.1200/JCO.2007.13. 2183 (Pubitemid 350232254)
7. Folprecht G., Lutz M. P., Schöffski P., Seufferlein T., Nolting A., Pollert P., Köhne C. H., Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma. Annals of Oncology 2006 17 3 450 456 2-s2.0-33644697486 10.1093/annonc/mdj084 (Pubitemid 43329582)
8. Kopetz S., Chang G. J., Overman M. J., Eng C., Sargent D. J., Larson D. W., Grothey A., Vauthey J. N., Nagorney D. M., McWilliams R. R., Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. Journal of Clinical Oncology 2009 27 22 3677 3683 2-s2.0-68949094312 10.1200/JCO.2008.20.5278
9. Fernandez F. G., Drebin J. A., Linehan D. C., Dehdashti F., Siegel B. A., Strasberg S. M., Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Annals of Surgery 2004 240 3 438 450 2-s2.0-4344615981 10.1097/01.sla.0000138076.72547.b1 (Pubitemid 39121338)
10. Fusai G., Davidson B. R., Strategies to increase the resectability of liver metastases from colorectal cancer. Digestive Surgery 2003 20 6 481 496 2-s2.0-0142165851 10.1159/000073535 (Pubitemid 37329219)
11. Nordlinger B., Sorbye H., Glimelius B., Poston G. J., Schlag P. M., Rougier P., Bechstein W. O., Primrose J. N., Walpole E. T., Finch-Jones M., Jaeck D., Mirza D., Parks R. W., Collette L., Praet M., Bethe U., Van Cutsem E., Scheithauer W., Gruenberger T., Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. The Lancet 2008 371 9617 1007 1016 2-s2.0-40749149728 10.1016/S0140-6736(08)60455-9 (Pubitemid 351392040)
12. Vermeulen P. B., Colpaert C., Salgado R., Royers R., Hellemans H., Van Den Heuvel E., Goovaerts G., Dirix L. Y., Van Marck E., Liver metastases from colorectal adenocarcinomas grow in three patterns with different angiogenesis and desmoplasia. Journal of Pathology 2001 195 3 336 342 2-s2.0-0034782184 10.1002/path.966 (Pubitemid 32998359)
13. Stessels F., Van den Eynden G. G., Van den Auwera I., Salgado R., Van den Heuvel E., Harris A. L., Jackson D. G., Colpaert C. G., Van Marck E. A., Dirix L. Y., Vermeulen P. B., Breast adenocarcinoma liver metastases, in contrast to colorectal cancer liver metastases, display a non-angiogenic growth pattern that preserves the stroma and lacks hypoxia. British Journal of Cancer 2004 90 7 1429 1436 2-s2.0-2342584137 10.1038/sj.bjc.6601727 (Pubitemid 38586273)
14. Illemann M., Bird N. C., Majeed A. W., Lærum O. D., Lund L. R., Dano K., Nielsen B. S., Two distinct expression patterns of urokinase, urokinase receptor and plasminogen activator inhibitor-1 in colon cancer liver metastases. International Journal of Cancer 2009 124 8 1860 1870 2-s2.0-62449284577 10.1002/ijc.24166
15. Illemann M., Bird N. C., Majeed A. W., Sehested M., Laerum O. D., Lund L. R., Dano K., Nielsen B. S., MMP-9 is differentially expressed in primary human colorectal adenocarcinomas and their metastases. Molecular Cancer Research 2006 4 5 293 302 2-s2.0-33744797077 10.1158/1541-7786.MCR-06-0003 (Pubitemid 43837330)
16. Illemann M., Hansen U., Nielsen H. J., Andrease P. A., Hoyer-Hansen G., Lund L. R., Dano K., Nielsen B. S., Leading-edge myofibroblasts in human colon cancer express plasminogen activator inhibitor-1. American Journal of Clinical Pathology 2004 122 2 256 265 2-s2.0-3242753364 10.1309/F32X-WQ20-T568-H8VP (Pubitemid 38971359)
17. Pyke C., Kristensen P., Ralfkiaer E., Grondahl-Hansen J., Eriksen J., Blasi F., Dano K., Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. American Journal of Pathology 1991 138 5 1059 1067 2-s2.0-0025853770
18. Paku S., Lapis K., Morphological aspects of angiogenesis in experimental liver metastases. American Journal of Pathology 1993 143 3 926 936 2-s2.0-0027757090 (Pubitemid 24058248)
19. Solaun M. S., Mendoza L., De Luca M., Gutierrez V., López M. P., Olaso E., Lee Sim B. K., Vidal-Vanaclocha F., Endostatin inhibits murine colon carcinoma sinusoidal-type metastases by preferential targeting of hepatic sinusoidal endothelium. Hepatology 2002 35 5 1104 1116 2-s2.0-0036240304 10.1053/jhep.2002.32528 (Pubitemid 34454007)
20. Van den Eynden G. G., Bird N. C., Majeed A. W., Van Laere S., Dirix L. Y., Vermeulen P. B., The histological growth pattern of colorectal cancer liver metastases has prognostic value. Clinical and Experimental Metastasis 2012 29 6 541 549
21. Ronne E., Hoyer-Hansen G., Brunner N., Pedersen H., Rank F., Osborne C. K., Clark G. M., Dano K., Grondahl-Hansen J., Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Research and Treatment 1995 33 3 199 207 2-s2.0-0028955894 10.1007/BF00665944
22. Plesner T., Ploug M., Ellis V., Ronne E., Hoyer-Hansen G., Wittrup M., Pedersen T. L., Tscherning T., Dano K., Hansen N. E., The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct intracellular compartments to the plasma membrane on stimulation of human neutrophils. Blood 1994 83 3 808 815 2-s2.0-0028031885 (Pubitemid 24043743)
23. Laerum O. D., Ovrebo K., Skarstein A., Christensen I. J., Alpizar-Alpizar W., Helgeland L., Dano K., Nielsen B. S., Illemann M., Prognosis in adenocarcinomas of lower oesophagus, gastro-oesophageal junction and cardia evaluated by uPAR-immunohistochemistry. International Journal of Cancer 2012 131 3 558 569
24. Alpizar-Alpizar W., Christensen I. J., Santoni-Rugiu E., Skarstein A., Ovrebo K., Laerum O. D., Urokinase plasminogen activator receptor on invasive cancer cells: a prognostic factor in distal gastric adenocarcinoma. International Journal of Cancer 2012 131 4 E329 E336
25. Sardari Nia P., Hendriks J., Friedel G., Van Schil P., Van Marck E., Distinct angiogenic and non-angiogenic growth patterns of lung metastases from renal cell carcinoma. Histopathology 2007 51 3 354 361 2-s2.0-34548136213 10.1111/j.1365-2559.2007.02800.x (Pubitemid 47301631)
26. Sardari Nia P., Colpaert C., Vermeulen P., Weyler J., Pezzella F., Van Schil P., Van Marck E., Different growth patterns of non-small cell lung cancer represent distinct biological subtypes. Annals of Thoracic Surgery 2008 85 2 395 405 2-s2.0-38349155817 10.1016/j.athoracsur.2007.08.054
27. Jubb A. M., Cesario A., Ferguson M., Congedo M. T., Gatter K. C., Lococo F., Mulè A., Pezzella F., Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer 2011 104 12 1877 1881 2-s2.0-79958148848 10.1038/bjc.2011.147
28. Benjamin L. E., Golijanin D., Itin A., Pode D., Keshet E., Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. The Journal of Clinical Investigation 1999 103 2 159 165 2-s2.0-0032952010 (Pubitemid 29053133)
29. Eberhard A., Kahlert S., Goede V., Hemmerlein B., Plate K. H., Augustin H. G., Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies. Cancer Research 2000 60 5 1388 1393 2-s2.0-0034161989 (Pubitemid 30152012)
30. Shah M. A., Khanin R., Tang L., Janjigian Y. Y., Klimstra D. S., Gerdes H., Kelsen D. P., Molecular classification of gastric cancer: a new paradigm. Clinical Cancer Research 2011 17 9 2693 2701 2-s2.0-79955500519 10.1158/1078-0432.CCR-10-2203
31. Halama N., Michel S., Kloor M., Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy. Cancer Research 2011 71 17 5670 5677
32. Saltz L. B., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T. S., Rivera F., Couture F., Sirzén F., Cassidy J., Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. Journal of Clinical Oncology 2008 26 12 2013 2019 2-s2.0-42949149159 10.1200/JCO.2007.14.9930
33. Cassidy J., Clarke S., Díaz-Rubio E., Scheithauer W., Figer A., Wong R., Koski S., Lichinitser M., Yang T. S., Rivera F., Couture F., Sirzén F., Saltz L., Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. Journal of Clinical Oncology 2008 26 12 2006 2012 2-s2.0-42949150908 10.1200/JCO.2007.14.9898
34. Lièvre A., Bachet J. B., Le Corre D., Boige V., Landi B., Emile J. F., Côté J. F., Tomasic G., Penna C., Ducreux M., Rougier P., Penault-Llorca F., Laurent-Puig P., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Research 2006 66 8 3992 3995 2-s2.0-33646228635 10.1158/0008-5472.CAN-06-0191
35. Thibodeau S. N., French A. J., Cunningham J. M., Tester D., Burgart L. J., Roche P. C., McDonnell S. K., Schaid D. J., Vockley C. W., Michels V. V., Farr G. H., O'Connell M. J., Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Research 1998 58 8 1713 1718 2-s2.0-0032522658 (Pubitemid 28215098)
36. Samowitz W. S., Curtin K., Ma K. N., Schaffer D., Coleman L. W., Leppert M., Slattery M. L., Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiology Biomarkers and Prevention 2001 10 9 917 923 2-s2.0-0034852772 (Pubitemid 32844897)
37. Sinicrope F. A., Sargent D. J., Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications. Clinical Cancer Research 2012 18 6 1506 1512
38. Ribic C. M., Sargent D. J., Moore M. J., Thibodeau S. N., French A. J., Goldberg R. M., Hamilton S. R., Laurent-Puig P., Gryfe R., Shepherd L. E., Tu D., Redston M., Gallinger S., Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. The New England Journal of Medicine 2003 349 3 247 257 2-s2.0-0038002279 10.1056/NEJMoa022289 (Pubitemid 36859476)
39. Fuchs E., Das sarkom des uvealtractus. Graefe's Archive for Clinical and Experimental Ophthalmology 1882 12 2 233
40. Paget S., Distribution of secondary growths in cancer of the breast. The Lancet 1889 1 571 573 2-s2.0-50549121134